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Pathophysiology and Clinical Application of the Renin 
System: Early Steps Toward Personalized Medicine
Fritz R. Bühler1
John H. Laragh was a visionary translational scientist, from 
bench to bedside. During his entire life, he worked on fitting 
together the complex cybernetic system of renin-angiotensin 
vasoconstriction and the commensurate angiotensin-aldos-
terone sodium-volume homeostasis and renal potassium 
control. It was John Laragh who infused subpressor doses of 
angiotensin into man and demonstrated the attendant rise of 
aldosterone secretion.1 (By the way, both angiotensin peptides 
and aldosterone had been synthetized at CIBA (now fused 
with Sandoz to Novartis) where Franz Gross played a pivotal 
role and interacted frequently with John Laragh.) The question 
always was—still is?—whether, functionally, the renin system 
is an archaic bystander (e.g., for severe blood volume or salt 
loss) or is pathophysiologically involved in fine-tuning car-
diovascular control and the regulation of normal and elevated 
blood pressure? John Laragh devoted his professional and 
scientific life to this question. His laboratory power and his 
many clinical fellows, mostly from Europe, were put behind it 
with the support of major National Institutes of Health grants. 
I had the great pleasure of being a member of that elitist, com-
petitive yet collegial Laragh Family team during John Laragh’s 
most productive years (1970–1974) (see authors of ref. 3–5).
GENESIS OF THE RENIN-SODIUM INDEX
In the early 1970s, great care was spent measuring with great 
precision and characterizing the hormonal factors involved in 
the renin system: renin, plasma renin activity (PRA), the differ-
ent angiotensin peptides, particularly angiotensin II (octapep-
tide), the most powerful vasoconstrictor, as well as aldosterone 
in urine and plasma; the latter was one of my own lab tasks.2 
Behind all bench work in John Laragh’s lab was a woman, as 
behind every strong man, Jean Sealey, with her strong and 
critical scientific mind and her technical talents. We all learned 
a great deal from John Laragh, as well as each other, but Jean 
Sealey was the master of quality and scientific rigor.
One of the questions was how to relate PRA (with a 100-
fold gain from 0.2 ng/ml/hour (if you can measure it at all) 
to 20 ng/ml/hour to normal and hypertensive people? There 
was relentless work. Hans R.  Brunner carried the ball (a 
colleague from Basel; both our fathers had worked in the 
pharmaceutical industry!) in carrying out metabolic stud-
ies of normal and hypertensive subjects who ingested a wide 
range of sodium intakes and in whom PRA was related to 
24-hour urinary sodium excretion rates. We found a roughly 
semiparabolic relationship but, despite the help of a math-
ematics professor, were unable to define the relationship 
in mathematical terms. We therefore arbitrarily identified 
the “waterfall-like” boundaries of this renin–sodium rela-
tionship in normotensive individuals and then defined the 
renin–sodium index in patients with so-called essential 
hypertension. PRA measurements were performed before 
treatment—possible at that time!—or after a 3-week washout 
period. Approximately 30% of hypertensive patients had low 
renin, 55% were “normal” (in fact too high for their elevated 
blood pressure), and 15% had high PRA. In a landmark arti-
cle, the 3 renin subtypes of hypertension were defined, as 
was increased cardiovascular mortality in the high-renin 
compared with the low-renin patients.3 This all happened 
under the merciless analytical scrutiny of John H. Laragh.
RENIN-SUPPRESSIVE POWER OF BETA-ADRENOCEPTOR 
BLOCKERS
At that time (Figure 1), a paper was published showing that 
beta-blockers suppress renin secretion in dogs. John Laragh 
wanted to test whether propranolol (the only beta-blocker 
available in the United States) had antihypertensive effects 
in the 3 renin subgroups. Because I  had experience with 
oxprenolol (from CIBA) at the University of Basel, I was put 
in charge of treating the first patients without knowing the 
renin type. Many more patients followed. In all, I analyzed the 
responses of 48 of them. Propranolol lowered blood pressure 
in the high-renin patients and did so to a lesser degree in the 
normal-renin patients, whereas patients with low renin did 
not benefit much; indeed some had increased blood pressure.4
Later we found a direct relationship between the fall in 
renin and the fall in blood pressure.5 This was shown with 
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other beta-blockers alone or in combination with diuretics.6 
In the early 1970s, the use of a beta-blocker for antihyperten-
sive monotherapy was heretic because beta-blockers weaken 
the heart because of their negative inotropic effect; to play 
it safe, beta-blockers were almost always combined with a 
diuretic. This report4 revolutionized antihypertensive treat-
ment and for a number of years was the most cited clini-
cal research article in the International Citation Index. But, 
by that time I  had moved on to testing saralasin, the first 
angiotensin receptor blocker, and teprotide, the prototype 
angiotensin-converting enzyme inhibitor. These drugs had 
to be given intravenously because they were not orally active. 
They confirmed the propranolol story. John Laragh’s renin–
sodium index and the differential use of antihypertensive 
drugs based on PRA levels opened the way to pathophysi-
ological therapy in essential hypertension, practically antici-
pating personalized medicine.
RENIN–ENDOCRINE ARM OF THE SYMPATHETIC 
NERVOUS SYSTEM
When I left John Laragh’s group as a fellow in 1974 I knew 
that I had a good friend. To this day, we still talk about our 
mutual interests. Meanwhile the next generation of Laragh’s 
Figure 1. John H. Laragh (left) and Fritz R. Bühler in one of many ardent debates during a 1980 visit to New York.
Figure 2. John H. Laragh (left) and Fritz R. Bühler continuing ardent, although somewhat more relaxed, debates in the Village of Golf, Florida, Fall 2010.
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trainees continued to work in New York, whereas the rest 
of us returned to our own institutions to continue further 
work on the antihypertensive mode of action of renin-
angiotensin system inhibition: after beta-blockers, there 
were orally active angiotensin-converting enzyme inhibi-
tors, angiotensin receptor blockers, and lately the renin 
inhibitors.7 John said that it’s almost impossible to “cheat” 
the renin axis completely, and research showed that there 
are always compensatory mechanisms following each site of 
inhibition.
Back at the University of Basel, we explored how the 
beta-adrenoceptors–mediated renin system activation 
interplayed with the sympathetic nervous system, adren-
ergic receptors, and ionic channels–mediated control of 
vasoconstriction. (We applied a forearm perfusion model 
in man.8) Because of John Laragh’s concepts—and Arthur 
Guyton’s work in Jackson, Mississippi—we viewed cardio-
vascular regulation as a cybernetic interaction of different 
systems for blood pressure control, ultimately mediated by 
intracellular calcium.9 Over many years, John Laragh—
often together with Jean Sealey—became a unique and 
most critical sounding board for our own research con-
cepts in Basel.
REGULATION OF PLATELET CALCIUM, ANALOGIES TO 
VASCULAR SMOOTH MUSCLE CELLS
Human platelets have many subcellular mechanisms 
in common with vascular smooth muscle cells: they have 
surface angiotensin receptors and a number of other con-
trol mechanisms that can be readily studied ex vivo.10 
They have actin and myosin interaction that causes them 
to contract and change their shape.9,11 In the late 1970s, 
single cell measurement of ionic fluxes became avail-
able,12 enabling measurement of intercellular Ca++ con-
centrations.9 We considered the platelets to be “swimming 
smooth muscle cells.” We studied the angiotensin effect on 
vascular composition and vascular matrix13 and the role of 
endothelium.14
CALCIUM ANTAGONIST FOR TREATMENT OF LOW-RENIN 
HYPERTENSION
Based on my work with Laragh’s group and the volume-
vasoconstriction paradigm,15 we sought to find an antihy-
pertensive tool to attack the volume-factor—other than with 
the well-known diuretics,16 which were reported to increase 
heart attacks in high doses.17
In the forearm perfusion model, we found that the degree 
of vasodilation during infusion of the calcium-antagonist 
verapamil was inversely related to baseline PRA.18 This led 
to the demonstration that, like diuretics, calcium antago-
nists—all 3 types—lower blood pressure most effectively in 
low-renin patients19 and are complementary as well as addi-
tive in combination with renin-angiotensin system block-
ers.20 Thus we showed that the renin–sodium index forecasts 
the antihypertensive response to calcium antagonists. Based 
on this work, John Laragh designated calcium antagonists as 
antivolume (anti-V) drugs.7
JOHN H. LARAGH: A CHARISMATIC ROLE MODEL
I worked with John Laragh for 4  years, and this influ-
enced my life and my entire career. When I arrived in the 
lab in 1970, it was difficult to gain access to his thinking, 
but he liked the European work attitude, even if he ignored 
those unable to speak English proficiently. I was pretty much 
a novice in both clinical and bench research but had solid 
bedside training in internal medicine. Unfortunately, the 
English language was not my forte, and in the early weeks 
John almost refused to talk to me. But, he came around when 
he saw my expertise with patients.
John Laragh was a creative thinker and excellent writer 
(and editor) with a warm-hearted and sometimes boyish 
charm. It was fun to see him swaying through hospital cor-
ridors, singing or whistling, and we copied him for a while. 
During these days, it became clear to us that John would 
marry Jean Sealey, DSc, his laboratory head, an elegant way 
to assure quality of scientific lab work. As Stanley Peart once 
said, “Most of us think that the renin test is important, John 
Laragh married it!” It is a pleasure and privilege to continue 
friendship with John (Figure 2) and Jean. John Laragh and 
his disciples triggered an avalanche of research in hyperten-
sion and particularly antihypertensive treatment, thereby 
reducing cardiovascular risk and improving health care. In 
my later capacity as the global head of clinical research and 
development at a major pharmaceutical company, the eco-
nomical impact of Laragh’s fermentative role became very 
obvious. John Laragh has impacted my personal life and 
my professional career more than anybody else. Thank you, 
John and Jean, ad multos annos. Ultima latet.
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